Latest News for Zozo Stock (OTC:SRTTY)

Zozo was established in 1998 by Yusaku Maezawa (founder and former CEO), and its main business is Zozotown, the largest fashion e-commerce platform in Japan. Zozotown's business consists mainly of consignment sales, where each brand's products are stocked in Zozotown's logistics bases, and brands open their shops on Zozotown as tenants. As of 2022, Zozotown sold clothing from over 8,500 brands and boasted about 9.3 million annual active users. In 2019, Zozo was acquired by Z Holdings. Since then, Zozo also sells through the Yahoo-owned general e-commerce site PayPay Mall.

News

Intraday Update

Markets

Movers

Trading Ideas

ACSAY

ADPXY

AGEEF

AGRIOS GLOBAL HLDGS LTD by Agrios Global Holdings Ltd.

AGGHF

ALLO

APEX

APYP

ARCH

ATRO

ATYG

AWCMY

AXAS

AXDDF

AXIM

BIOIF

BKSD

CASI

CCLP

CDSG

CEIX

CEQP

CGHC

CHYL

CNDT

CONN

COVTY

CRWOF

CTRA

CTXDF

CVGI

CVTI

CWLDF

CYPW

DTGI

EDRY

EGLE

EUTLF

FFIV

FLMN

FLWPF

FNHI

FTMDF

GCAN

GGIFF

GGTTF

GLKIF

GLOP

GLTC

GMLP

GNLN

GOCOF

GTEC

GVXXF

HGSH

HMLP

HRCXF

HRVOF

HSNGF

IMAC

IMII

ISUZY

ITCC

JAPSY

KATFF

KELYA

KLYCY

KRKR

KUKAY

LBHRF

MFCSF

MINE

MMEX

MMJJF

MNRO

MRKR

MRQRF

Stocks That Hit 52-Week Lows On Monday

AMHPF

AMSC

APRN

APTS

ARCB

AVGR

BCII

BKLRF

BRID

BRTX

BTUMF

CDZI

CLDT

CORE

CRWOY

China Shenhua Energy Unsponsored representing A shares

CSUAY

CTTMF

DIGP

DNOW

DTNOF

ELGX

ENTA

FOSL

FRBK

FSAM

GALT

GLBS

GLNG

GOOS

HAYN

INCY

IPWG

ITAYY

JFIN

JNPR

KSRYY

LGYV

LNGLY

LQDT

LTMCF

LTRPA

MNOV

MOBQ

METALLIS RESOURCES INC by Metallis Resources, Inc.

MTLFF

MYSZ

NDBKY

NEPT

NGVT

NHTC

NOVN

NTEC

OGSM

OMER

PAGP

PCFBY

PDNLA

PGAS

Stocks That Hit 52-Week Lows On Friday

Zozo Inc

Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares are trading lower by 20.7% to $4.92 during Monday&#8217;s session after the company announced the exercise of warrants for $4.4 million in <a href="https://www.benzinga.com/pressreleases/24/04/g38487322/avenue-therapeutics-announces-exercise-of-warrants-for-4-4-million-in-gross-proceeds">gross proceeds</a>.
These warrants were issued at different times with various exercise prices, but the warrant holders have agreed to exercise them at a reduced price of $6.20 per share. The company expects to receive approximately $4.4 million in gross proceeds from this exercise. 
In return for exercising the warrants, Avenue will issue new unregistered Series C and Series D warrants to the warrant holders, each allowing them to purchase up to 689,680 shares of common stock at an exercise price of $6.20 per share. 
The new Series C warrants will be exercisable immediately and valid for five years, while the Series D warrants will be exercisable immediately but valid for eighteen months. The transaction is expected to close around May 1, 2024, subject to standard closing conditions.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38488420/broadcom-marvell-set-to-capitalize-on-ai-investments-from-microsoft-alphabet-meta-j">Broadcom, Marvell Set To Capitalize On AI Investments From Microsoft, Alphabet, Meta: JPMorgan</a>
<h2 class="wp-block-heading">Should I Sell My ATXI Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Avenue Therapeutics have decreased by 93.29% in the past year. An investor who bought shares of Avenue Therapeutics at the beginning of the year would take a loss of $7.05 per share if they sold it today. The stock has fallen 56.03% over the past month, meaning an investor who bought shares on Mar. 1 would see a capital loss of $6.95.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Avenue Therapeutics stock currently has an RSI of 27.91, indicating oversold conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
ATXI has a 52-week high of $93.75 and a 52-week low of $4.77.

ATXI

Why Avenue Therapeutics (ATXI) Stock Is Falling Sharply

WIIM

SGHT

Sight Sciences shares are trading higher after the company announced a $34 million patent infringement verdict against Alcon and its Hydrus Microstent.

Compass Point analyst Floris Van Dijkum maintains Phillips Edison (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PECO#NASDAQ">PECO</a>) with a Neutral and lowers the price target from $39 to $36.

Price Target

Analyst Ratings

PECO

Compass Point Maintains Neutral on Phillips Edison, Lowers Price Target to $36

The European Union has expressed concerns over the potential anti-competitive effects of the&nbsp;International Consolidated Airlines Group&#8217;s&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ICAGY#OTC">ICAGY</a>) planned acquisition of Air Europa, valued at approximately $427.7 million.&nbsp;
The acquisition aims to enhance IAG&#8217;s&nbsp;presence in the&nbsp;Spanish and Latin American&nbsp;markets.
Late on Friday, the European Commission expressed concerns that the merger between International Consolidated Airlines Group and Air Europa might&nbsp;result in increased prices and reduced&nbsp;service quality for air travelers, particularly on routes within and to and from Spain.
The preliminary findings of the Commission&#8217;s investigation indicate that the consolidation could substantially restrict competition in the passenger air transport market, potentially leading to higher costs and diminished service quality for consumers following the transaction.
In response to these concerns, the European Commission&nbsp;has issued a&nbsp;<a target="_blank" href="https://ec.europa.eu/commission/presscorner/detail/sw/ip_24_2306" rel="noreferrer noopener">formal&nbsp;</a>statement of objections.&nbsp;
IAG can propose measures to resolve the initial competition concerns noted by the Commission and may submit these solutions at any point during the proceedings&nbsp;up until the deadline on&nbsp;June 10, 2024.
&#8220;Compared with the remedy package we submitted in our previous attempt to acquire Air Europa, we are doubling our offer in terms of divested capacity,&#8221;&nbsp;a WSJ&nbsp;<a target="_blank" href="https://www.wsj.com/business/airlines/iag-bid-to-buy-air-europa-could-harm-competition-eu-says-cac3fde2?mod=business_lead_pos3" rel="noreferrer noopener">report</a>&nbsp;cited IAG.
Price Action: ICAGY shares traded lower by 0.80% at $4.33 at last check Monday.
Image credit: Dall-E 3

Equities

Regulations

Media

Internationalnsolidated Airlines Group Sponsored American Depository Receipt

ICAGY

IAG's Acquisition Of Air Europa Under Scrutiny For Competition Concerns

BMRA

Biomerica shares are trading higher after the company announced an exclusive distribution agreement with a UAW healthcare conglomerate.

SINTX Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares are trading higher by 32% to $0.05 during Monday&#8217;s session after the company and Prodways Printers announced they have entered into a technical partnership and ceramic slurry <a href="https://www.benzinga.com/pressreleases/24/04/g38489876/sintx-and-prodways-agree-on-ceramic-slurry-supply-and-3d-printing-agreement">supply agreement</a>.
Under this collaboration, SINTX and its subsidiary will provide ceramic-filled printable slurries to Prodways and aid in process development and customer support. SINTX says this partnership enables comprehensive collaboration in advanced technical ceramics, especially in casting applications.
Ann Kutsch, the General Manager of the SINTX-Maryland site, expressed confidence in their engineering team&#8217;s six-year experience with Prodways printers. They&#8217;ve commercialized various resin compositions and part designs using Prodways equipment. 
Kutsch anticipates that a formal partnership with Prodways will foster breakthrough developments and innovative solutions for their customers.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38488420/broadcom-marvell-set-to-capitalize-on-ai-investments-from-microsoft-alphabet-meta-j">Broadcom, Marvell Set To Capitalize On AI Investments From Microsoft, Alphabet, Meta: JPMorgan</a>
<h2 class="wp-block-heading">How To Buy SINT Stock</h2>
By now you're likely curious about how to participate in the market for SINTX &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href='https://www.benzinga.com/money/best-stock-trading-platforms'>possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of SINTX, which is trading at $0.05 as of publishing time, $100 would buy you 2000.0 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SINT has a 52-week high of $1.82 and a 52-week low of $0.02.

SINT

Why SINTX Technologies Shares Are Skyrocketing

Compass Point analyst Casey Alexander maintains Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) with a Neutral and lowers the price target from $490 to $390.

KNSL

Compass Point Maintains Neutral on Kinsale Cap Gr, Lowers Price Target to $390

Wedbush analyst David Chiaverini maintains First Foundation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FFWM#NYSE">FFWM</a>) with a Neutral and lowers the price target from $8 to $7.

FFWM

Wedbush Maintains Neutral on First Foundation, Lowers Price Target to $7

Monday,&nbsp;Addex Therapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) released top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38481199/addex-provides-update-on-adx71149-phase-2-epilepsy-study" rel="noreferrer noopener">levetiracetam or brivaracetam</a>.&nbsp;
The company&nbsp;is collaborating&nbsp;with&nbsp;Johnson &amp; Johnson&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)&nbsp;Janssen Pharmaceuticals Inc.
The Phase 2 study did not achieve statistical significance for the primary endpoint&nbsp;of&nbsp;time&nbsp;for&nbsp;patients to reach baseline seizure count when ADX71149 was added to the standard of care.
&#8220;While disappointed that the Phase 2 ADX71149 epilepsy study did not meet the primary endpoint, we are still analyzing the data,&#8221; said Roger Mills,&nbsp;Chief Medical Officer of Addex.&nbsp;
&#8220;We will provide details on data from the full study when this analysis is completed and will work with our partner to determine the next steps for the ADX71149 program,&#8221; Mills added.
The data were reported&nbsp;from a total of 110 evaluable patients, who each received either 50 mg or 100 mg of ADX71149 twice daily (100 mg or 200mg twice daily, respectively, for patients receiving CYP3A4 inducing anti-seizure medication) in addition to their standard dose of levetiracetam or brivaracetam and up to three other anti-seizure drugs.&nbsp;
Adjunctive administration of ADX71149 was safe and well tolerated.
&#8220;While this is disappointing news for us and our partner, Janssen, we remain focused on advancing the rest of our portfolio of allosteric modulator programs toward clinical studies,&#8221; said Tim Dyer, CEO of Addex. &#8220;In particular, we are making great progress in our GABAB PAM collaboration with Indivior, which is on track to select drug candidates for IND enabling studies in June this year for substance use disorder and chronic cough programs.&#8221;
Price Action: ADXN shares are down 50.4% at $7.99 at the last check Monday.
PublicDomainPictures from Pixabay

Biotech

Large Cap

Health Care

General

ADXN

Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks

ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares are trading higher Monday after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with IC 100 to potentially attenuate cardiac <a href="https://www.benzinga.com/pressreleases/24/04/g38487200/zyversa-therapeutics-announces-publication-reinforcing-the-rationale-for-inhibiting-asc-with-ic-10">comorbidities in patients with Alzheimer&#8217;s Disease.</a>
The Details:
Researchers from the University of Miami Miller School of Medicine and inventors of Inflammasome ASC Inhibitor IC 100, published a scientific paper in the peer-reviewed journal, &#8220;Frontiers in Molecular Neuroscience&#8221;, highlighting how inflammasome-mediated inflammation in Alzheimer&#8217;s disease can trigger inflammation in the heart.
&#8220;This research reinforces the importance of attenuating activation of multiple types of inflammasomes that govern the inflammatory response in AD and mediating systemic inflammatory signals in EVs to control the spread of damaging inflammation to cardiovascular and other cells,&#8221; commented Stephen C. Glover, ZyVersa&#8217;s CEO.&nbsp;
&#8220;ZyVersa&#8217;s Inflammasome ASC inhibitor IC 100 is designed to inhibit formation of multiple types of inflammasomes to attenuate initiation of the inflammatory cascade and to inhibit their associated ASC specks to reduce spread and perpetuation of damaging inflammation,&#8221; Glover added.&nbsp;
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, ZyVersa effected a reverse stock split with a ratio of 1-for-20 last Friday leaving the stock with a float of less than 758,000 shares.&nbsp;
Related News: <a href="https://www.benzinga.com/news/24/04/38469297/whats-going-on-with-immunitybio-stock">What&#8217;s Going On With ImmunityBio Stock?</a>
<h2 class="wp-block-heading">Is ZVSA A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/ZVSA">ZyVersa Therapeutics</a>&#8216; page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. ZyVersa Therapeutics does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 9.75%, you'll need to buy a share of Allspring Inc Opps by the May 10. Once done, you can expect to receive a nominal payout of $0.05 on June 3.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href='https://www.benzinga.com/quote/ZVSA'>ZyVersa Therapeutics</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
ZVSA Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, ZyVersa shares are up 22.5% at $6.11 at the time of publication Monday.
Image: : Phoenix Locklear from Pixabay

Penny Stocks

ZVSA

What's Going On With ZyVersa Stock?

CJS Securities initiates coverage on Thermon Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THR#NYSE">THR</a>) with a Market Outperform rating and announces Price Target of $42.

Initiation

CJS Securities Initiates Coverage On Thermon Group Holdings with Market Outperform Rating, Announces Price Target of $42

ANVS

Annovis Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Down -48.1%

Wedbush analyst David Chiaverini maintains Valley Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLY#NASDAQ">VLY</a>) with a Neutral and lowers the price target from $9 to $8.

Wedbush Maintains Neutral on Valley Ntl, Lowers Price Target to $8

Annovis Bio shares are trading lower after the company announced data from its Phase II/III Alzheimer study of buntanetap in mild to moderate Alzheimer's. Efficacy in the CGIC endpoint was not reached due to the limited number of patients and short trial duration.

Canaccord Genuity analyst Jason Tilchen maintains PENN Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) with a Buy and lowers the price target from $32 to $28.

PENN

Canaccord Genuity Maintains Buy on PENN Entertainment, Lowers Price Target to $28

RVTY

Revvity shares are trading higher after the company reported better-than-expected Q1 financial results.

U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose sharply during Monday's session on reports the company will partner with Baidu for mapping and navigation for <a href="https://www.benzinga.com/markets/equities/24/04/38485399/tesla-skyrockets-about-10-in-premarket-whats-fueling-the-dramatic-rally">Full Self-Driving in China</a>.
Tesla shares jumped 10.5% to $185.94 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Deciphera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCPH#NASDAQ">DCPH</a>) shares surged 73% to $25.36 after the company announced it will be acquired by ONO Pharmaceutical for $25.60 per share in cash.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) shares rose 36.3% to $10.02. ImmunityBio shares jumped around 44% on Friday after the company announced overall survival results in its QUILT 3.055 study.</li>
<li>Koninklijke Philips N.V.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) shares gained 35.5% to $28.56 after the company announced $1.1 billion settlement for Respironics personal injury and medical monitoring litigation. The company also reported better than expected first-quarter earnings and reaffirmed guidance.</li>
<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) shares jumped 31.1% to $49.66 after the company announced it received Breakthrough Therapy Designation from the FDA for DCCR extended-release tablets in Prader-Willi Syndrome.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) gained 20.7% to $7.53.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) jumped 20% to $3.38.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) climbed 19% to $1.0250.</li>
<li>Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) rose 17.7% to $14.98. Zoetis announced plans to sell its medicated feed additive portfolio to Phibro Animal Health for $350 million.</li>
<li>Heartland Financial USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTLF#NASDAQ">HTLF</a>) rose 17.2% to $41.86 after UMB Financial announced it will acquire the company.</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) gained 14.6% to $50.08.</li>
<li>Arcadium Lithium plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NASDAQ">ALTM</a>) rose 14.5% to $4.45.</li>
<li>MultiPlan Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) jumped 14% to $0.6566. MultiPlan said it will release its first quarter 2024 financial results on Wednesday, May 8.</li>
<li>Exscientia plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAI#NASDAQ">EXAI</a>) rose 12.7% to $4.5399.</li>
<li>Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) gained 11.2% to $4.9182 on FDA clearance of its IND application for PM359.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) climbed 10.7% to $28.02. Cullinan Therapeutics announced appointment of Mary Kay Fenton as Chief Financial Officer.</li>
<li>Fulton Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) gained 9.3% to $17.07. Republic First Bancorp has been seized by U.S. regulators and sold to Fulton Bank, a unit of Fulton Financial Corp.</li>
<li>Tellurian Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TELL#NYSE">TELL</a>) gained 7.7% to $0.5031.</li>
<li>Medifast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) rose 7% to $36.07.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) rose 6.2% to $1.56.</li>
<li>Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) gained 6% to $123.86, possibly on reports indicating Saudi Arabia is looking to obtain lithium from abroad for its EV efforts.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) rose 5.7% to $37.21 after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $21 to $45.</li>
<li>Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) rose 4.8% to $12.48  on reports of the Redstone family and David Ellison making concessions to investors, with Ellison reportedly proposing to purchase a block of shares at a premium.</li>
<li>GrafTech International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NASDAQ">EAF</a>) gained 4.4% to $1.65.        </li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) rose 4.1% to $58.65. Seaport Global analyst David Joyce upgraded Roku from Neutral to Buy and announced a $74 price target.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/04/38489087/jim-cramer-likes-palantir-recommends-pioneer-natural-resources-i-want-you-to-ka-ching-ka-ching">Jim Cramer Likes Palantir, Recommends Pioneer Natural Resources: &#8216;I Want You To Ka-Ching, Ka-Ching&#8217;</a>

ALTM

Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Zozo Stock (OTC:SRTTY)

Monday, February 03, 2020

Friday, January 31, 2020